Thanks very much.
and I will continue along that line of questioning. This is about transparency.
Listen, I know I'm here as a parliamentarian, but on behalf of the average Canadian, what it appears to me that you're saying in a multitude of different ways—and I don't believe that you're trying to be obtuse in your answers—is that the future vision of pharmacare would suggest that Canada's drug agency would do what the pCPA is doing now. Without understanding what the costly coalition's vision is, it becomes very difficult for me to understand what it is you're saying, not because I don't understand English—I do—but because your answer is obtuse without perhaps meaning to be.
I don't mean to be negative toward your answers, but I don't have an understanding of what the negotiated vision is, because you might have been part of it and we were not. We who represent the opposition were not part of that conversation around what the vision is on behalf of Canadians.
Do you know what? I think that Canadians deserve to know what the vision is. If the vision means that there's going to be a new national bulk purchasing strategy that will be under the purview of Canada's drug agency, then they need to hear that. If it's not, then the wording in this amendment, which talks about, as my colleague eloquently pointed out on page 4, I believe, paragraph 6, is specifically about diabetes and contraception, and it's also about the continuation of a national bulk purchasing strategy.
I'm going to ask you to be concrete, which I know you don't want to be—I understand that—but either this is the creation of a new pathway under the auspices of Canada's drug agency or the continuation of a national bulk purchasing strategy. I ask you, sir, on behalf of Canadians, which is it?